A phase 1a/b study of CB4211, a mitochondria based therapeutics (MBTs), in subjects with NASH and obesity with NAFLD.

Trial Profile

A phase 1a/b study of CB4211, a mitochondria based therapeutics (MBTs), in subjects with NASH and obesity with NAFLD.

Planning
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs CB 4211 (Primary)
  • Indications Obesity
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 20 Nov 2017 New trial record
    • 13 Nov 2017 According to a CohBar media release, the first mitochondrial based therapeutic in human trial is planned in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top